17,243 research outputs found
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
No full textIntroduction: Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited. Areas covered: This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010. Expert opinion: Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens. © 2011 Informa UK, Ltd.American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P388, DOI DOI 10.1164-RCCM.200405-644ST; Andrews J, 2007, J ANTIMICROB CHEMOTH, V60, P677, DOI 10.1093-jac-dkm242; *AST PHARM INC, 2009, VIBATIV TEL INJ; Barcia-Macay M, 2008, J ANTIMICROB CHEMOTH, V61, P1288, DOI 10.1093-jac-dkn120; Barriere Steven, 2004, Journal of Clinical Pharmacology, V44, P689, DOI 10.1177-0091270004266620; Boselli E, 2005, CRIT CARE MED, V33, P1529, DOI 10.1097-01.CCM.0000168206.59873.80; Chang FY, 2003, MEDICINE, V82, P333, DOI 10.1097-01.md.0000091184.93122.09; Conte JE, 2002, ANTIMICROB AGENTS CH, V46, P1475, DOI 10.1128-AAC.46.5.1475-1480.2002; Corey GR, 2009, NAT REV DRUG DISCOV, V8, P929, DOI 10.1038-nrd3051; Corey GR, 2010, CLIN INFECT DIS, V51, P641, DOI 10.1086-655827; Cruciani M, 1996, J ANTIMICROB CHEMOTH, V38, P865; *CUB PHARM INC, 2010, CUB DAPT INJ PACK IN; Draghi DC, 2008, ANTIMICROB AGENTS CH, V52, P2383, DOI 10.1128-AAC.01641-07; Draghi DC, 2008, J ANTIMICROB CHEMOTH, V62, P116, DOI 10.1093-jac-dkn124; File TM, 2010, CLIN INFECT DIS, V51, P1395, DOI 10.1086-657313; Freire AT, 2010, DIAGN MICR INFEC DIS, V68, P140, DOI 10.1016-j.diagmicrobio.2010.05.012; Gander S, 2005, J ANTIMICROB CHEMOTH, V56, P337, DOI 10.1093-jac-dki198; Georges H, 1997, EUR J CLIN MICROBIOL, V16, P385, DOI 10.1007-BF01726369; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P35, DOI 10.1592-phco.30.1.35; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P806, DOI 10.1592-phco.30.8.806; Goldstein EJC, 2004, ANTIMICROB AGENTS CH, V48, P2149, DOI 10.1128-ACC.48.6.2149-2152.2004; Gonzalez C, 1999, CLIN INFECT DIS, V29, P1171, DOI 10.1086-313440; Gotfried MH, 2008, ANTIMICROB AGENTS CH, V52, P92, DOI 10.1128-AAC.00875-07; Gradelski E, 2001, INT J ANTIMICROB AG, V18, P43, DOI 10.1016-S0924-8579(01)00343-0; Hatano K, 2007, J ANTIBIOT, V60, P709; Hegde SS, 2004, ANTIMICROB AGENTS CH, V48, P3043, DOI 10.1128-AAC.48.8.3043-3050.2004; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249; Hidayat LK, 2006, ARCH INTERN MED, V166, P2138, DOI 10.1001-archinte.166.19.2138; Higgins DL, 2005, ANTIMICROB AGENTS CH, V49, P1127, DOI 10.1128-AAC.49.3.1127-1134.2005; Honeybourne D, 2003, J ANTIMICROB CHEMOTH, V51, P1431, DOI 10.1093-jac-dkg262; Kalil AC, 2010, CRIT CARE MED, V38, P1802, DOI 10.1097-CCM.0b013e3181eb3b96; Kiem S, 2008, ANTIMICROB AGENTS CH, V52, P24, DOI 10.1128-AAC.00133-06; King A, 2004, J ANTIMICROB CHEMOTH, V53, P797, DOI 10.1093-jac-dkh156; Klevens RM, 2006, CLIN INFECT DIS, V42, P389, DOI 10.1086-499367; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378-chest.113.2.412; Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378-chest.128.6.3854; KUNKEL M, 2010, INF DIS SOC AM 48 AN; LAMER C, 1993, ANTIMICROB AGENTS CH, V37, P281; Leadbetter MR, 2004, J ANTIBIOT, V57, P326; Leonard SN, 2008, PHARMACOTHERAPY, V28, P458, DOI 10.1592-phco.28.4.458; Leuthner KD, 2006, J ANTIMICROB CHEMOTH, V58, P338, DOI 10.1093-jac-dkl235; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086-491709; Liu C, 2011, CLIN INFECT DIS, V52, pE18, DOI 10.1093-cid-ciq146; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P3315, DOI 10.1128-AAC.00113-08; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3731, DOI 10.1128-AAC.00101-07; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P2300, DOI 10.1128-AAC.01110-07; Lodise TP, 2009, CLIN INFECT DIS, V49, P507, DOI 10.1086-600884; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378-chest.111.3.676; Lunde CS, 2009, ANTIMICROB AGENTS CH, V53, P3375, DOI 10.1128-AAC.01710-08; Madrigal AG, 2005, ANTIMICROB AGENTS CH, V49, P3163, DOI 10.1128-AAC.49.8.3163-3165.2005; Mendes RE, 2010, INT J ANTIMICROB AG, V36, P374, DOI 10.1016-j.ijantimicag.2010.05.016; Mimoz O, 2006, INTENS CARE MED, V32, P775, DOI 10.1007-s00134-006-0136-3; Nannini EC, 2008, EXPERT OPIN PHARMACO, V9, P2197, DOI 10.1517-14656566.9.12.2197 ; Nguyen HA, 2009, ANTIMICROB AGENTS CH, V53, P1434, DOI 10.1128-AAC.01145-08; Odenholt I, 2007, ANTIMICROB AGENTS CH, V51, P3311, DOI 10.1128-AAC.01470-06; Pace JL, 2003, ANTIMICROB AGENTS CH, V47, P3602, DOI 10.1128-AAC.47.11.3602-3604.2003; Pertel PE, 2008, CLIN INFECT DIS, V46, P1142, DOI 10.1086-533441; Pfaller MA, 2010, J ANTIMICROB CHEMOTH, V65, P2396, DOI 10.1093-jac-dkq335; *PFIZ INC, 2010, ZYVOX LIN INJ LIN TA; Powers JH, 2004, CHEST, V126, P314, DOI 10.1378-chest.126.1.314; Putnam SD, 2010, DIAGN MICR INFEC DIS, V67, P359, DOI 10.1016-j.diagmicrobio.2010.03.009; Reyes N, 2006, J ANTIMICROB CHEMOTH, V58, P462, DOI 10.1093-jac-dkl222; Reyes N, 2005, ANTIMICROB AGENTS CH, V49, P4344, DOI 10.1128-AAC.49.10.4344-4346.2005; Rodvold KA, 2009, ANTIMICROB AGENTS CH, V53, P3294, DOI 10.1128-AAC.00144-09; Rotstein C, 2008, CAN J INFECT DIS MED, V19, P19; Rubinstein E, 2011, CLIN INFECT DIS, V52, P31, DOI 10.1093-cid-ciq031; Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086-491712; Sader HS, 2009, ANTIMICROB AGENTS CH, V53, P4127, DOI 10.1128-AAC.00616-09; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097-01.CCM.0000181731.53912.D9; Saravolatz LD, 2007, J ANTIMICROB CHEMOTH, V60, P406, DOI 10.1093-jac-dkm211; Shaw JP, 2010, ANTIMICROB AGENTS CH, V54, P3365, DOI 10.1128-AAC.01750-09; Shaw JP, 2005, ANTIMICROB AGENTS CH, V49, P195, DOI 10.1128-AAC.49.1.195-201.2005; Silverman JA, 2005, J INFECT DIS, V191, P2149, DOI 10.1086-430352; Sivagnanam S, 2003, CRIT CARE, V7, P119, DOI 10.1186-cc1871; Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086-524667; Steinkraus G, 2007, J ANTIMICROB CHEMOTH, V60, P788, DOI 10.1093-jac-dkm258; Stryjewski ME, 2006, ANTIMICROB AGENTS CH, V50, P862, DOI 10.1128-AAC.50.3.862-867.2006; Stryjewski ME, 2007, CLIN INFECT DIS, V44, P190, DOI 10.1086-510386; Stryjewski ME, 2008, CLIN INFECT DIS, V46, P1683, DOI 10.1086-587896; Stryjewski ME, 2005, CLIN INFECT DIS, V40, P1601, DOI 10.1086-429914; Stucki A, 2006, ANTIMICROB AGENTS CH, V50, P770, DOI 10.1128-AAC.50.2.770-773.2006; Sun HK, 2006, ANTIMICROB AGENTS CH, V50, P788, DOI 10.1128-AAC.50.2.788-790.2006; Tice AD, 2003, J ANTIMICROB CHEMOTH, V51, P1261, DOI 10.1093-jac-dkg186; Torres A, 2009, INTENS CARE MED, V35, P9, DOI 10.1007-s00134-008-1336-9; Tsuji BT, 2008, DIAGN MICR INFEC DIS, V60, P441, DOI 10.1016-j.diagmicrobio.2007.11.011; Wang GQ, 2006, J CLIN MICROBIOL, V44, P3883, DOI 10.1128-JCM.01388-06; Wong SL, 2010, PHARMACOTHERAPY, V30, P136, DOI 10.1592-phco.30.2.136; Wunderink RG, 2003, CHEST, V124, P1789, DOI 10.1378-chest.124.5.1789; *WYETH PHARM INC, 2010, TYGACIL TIG FOR INJ; 2009, DA 22 110 VIBATIV TE55
Rhodococcus equi endocarditis in immunocompetent hosts: report of the first two cases
No full textNo abstract presente nel lavor
The Story of "Me" Contemporary American Autofiction
No full textCover -- Title Page -- Copyright Page -- Contents -- Acknowledgments -- Introduction -- 1. Masculinity, Whiteness, and Postmodern Self-Consciousness -- 2. Rage against the Dying of the Author -- 3. The New Journalism as the New Fiction -- 4. Trauma Autofiction, Dissociation, and the Authenticity of "Real" Experience -- 5. Memoir vs. Autofiction as the Story of Me vs. the Story of "Me" -- Coda -- Appendix -- Notes -- References -- IndexDescription based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
No full textEthan Rubinstein,1 Martin E Stryjewski,2 Steven L Barriere31University of Manitoba, Winnipeg, MB, Canada; 2Department of Medicine, Section of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina; 3Theravance, Inc., South San Francisco, CA, USA Background: Hospital-acquired pneumonia (HAP) is the most common health care-associated infection contributing to death. Studies have indicated that there may be differences in the causative pathogens and outcomes of ventilator-associated pneumonia (VAP) and non-ventilator-associated pneumonia (NV-HAP). However, with limited NV-HAP-specific data available, treatment is generally based on data from studies of VAP. The Phase 3 Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) studies were two double-blind randomized controlled trials that demonstrated the non-inferiority of telavancin to vancomycin for treatment of Gram-positive HAP. We conducted a post hoc subgroup analysis of patients enrolled in the ATTAIN studies who had NV-HAP. Methods: Data from the two ATTAIN studies were pooled, and patients with NV-HAP were analyzed. The all-treated (AT) population consisted of all randomized patients who received ≥1 dose of study medication, and the clinically evaluable (CE) population consisted of AT patients who were protocol-adherent or who died on or after study day 3, where death was attributable to the HAP episode under study. The primary endpoint was clinical response (cure, failure, or indeterminate) at the follow-up/test of cure visit, conducted 7–14 days after the end of therapy. Results: A total of 1,076 patients (71.6% of overall ATTAIN AT population) had NV-HAP (533 and 543 patients in the telavancin and vancomycin treatment groups, respectively). Clinical cure rates in the CE population were similar for patients with NV-HAP treated with telavancin and vancomycin (83.1% [201/242] and 84.1% [233/277], respectively). In patients with methicillin-resistant Staphylococcus aureus isolated at baseline, cure rates in the CE population were 74.8% (77/103) for telavancin and 79.3% (96/121) for vancomycin. The incidence of adverse events, serious adverse events, and deaths in patients with NV-HAP was similar whether patients received telavancin or vancomycin. Conclusion: This post hoc subgroup analysis of the ATTAIN studies demonstrated similar cure rates for telavancin and vancomycin for treatment of NV-HAP. Keywords: nosocomial pneumonia, Staphylococcus aureus, methicillin-resistant Staphylococcus aureu
Remember Me A Novella about Finding Our Way to the Cross
No full textShades of Light.Cover -- Title Page -- Copyright -- Dedication Page -- Contents -- 1 The Word Became Flesh -- 2 The Gift of Myrrh -- 3 Taking the Cup -- 4 With a Kiss -- 5 Awakened -- 6 Accused -- 7 Bearing the Cross -- 8 Lament -- 9 Stripped -- 10 Pierced -- 11 It Is Finished -- 12 Into Your Hands -- 13 Buried -- 14 Risen -- Epilogue -- Journey to the Cross -- Acknowledgments -- Also Available -- Praise for Remember Me -- About the Author -- More Titles from InterVarsity PressShades of Light.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
"Test me and treat me" - attitudes to vitamin D deficiency and supplementation: a qualitative study
No full text© 2015 BMJ Open, "Test me and treat me"-attitudes to vitamin D deficiency and supplementation: a qualitative study. This manuscript version is made available under the Creative Commons Attribution Licens
Book of the month: Kennetta Hammond Perry's London is the Place for Me
No full textAuthor: Desmond L. Kemp Indiana University Purdue University Our book recommendation of the month is London is the Place for me whereby activism in London and America has been an ongoing challenge for Black people. Perry delivers a solid account of how post-war Afro-Caribbean migrants resisted British racism to establish their citizenship in England. The introduction begins with a calypso music tribute in "Windrush Politics", sets the tone of social history for migrants with a tale of the arr..
Remind Me to Investigate
No full textPolitical cartoon depicting United States Senator James O. Eastland of Mississippi dictating to his secretary, Remind Me to Investigate the Ole Miss Affair, My Findings Will Be as Follows; Source: unknown; Unknown datehttps://egrove.olemiss.edu/jws_clip/1054/thumbnail.jp
Dynamics of Network Formation Processes in the Co-Author Model
No full textThis article studies the dynamics in the formation processes of a mutual consent network in game theory setting: the Co-Author Model. In this article, a limited observation is applied and analytical results are derived. Then, 2 parameters are varied: the number of individuals in the network and the initial probability of the links in the network in its initial state. A simulation result shows a finding that is consistent with an analytical result for a state of equilibrium while it also shows different possible equilibria.Dynamics, Network, Game Theory, Model,Simulation, Equilibrium, Complexity
- …
